Floatz logo

Carboplatin

Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified

University of California, DavisSmall moleculePhase 2Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
89/ 100

Competitive context

89 Active assets in the Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified cohort.

Asset / SponsorPhaseRating
Ifosfamide
University of California, Davis
Phase 3BB
ETOPOSIDE
University of Washington
Phase 3BB
PREDNISONE TABLETS
National Cancer Institute (NCI)
Phase 3BB
VINCRISTINE SULFATE
National Cancer Institute (NCI)
Phase 2/3BB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
National Cancer Institute (NCI)
Phase 3BB

View all 50 →

Same molecule, other indications

Carboplatin is also rated in:

lung large cell carcinomaDormant
A
Indicative ·
80 / 100
View asset →
non-small cell squamous lung carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →